~~<i id='A2AA966094'><strike id='A2AA966094'><tt id='A2AA966094'><pre id='A2AA966094'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：entertainment 2025-09-28 08:34:38 Page View：58248

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The public health thinking behind the CDC’s new Covid guidance
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

leisure time

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

AdobeDiagnosticerrors—thatis,overlookingadisease,ordiagnosingiterroneouslyorlate—areaknownoccurrence

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

AdobeSomeofthecountry’sbiggesthealthinsurerssaidTuesdaythatuptoone-quarteroftheirclaimsarerunthrough